News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
690,317 Results
Type
Article (39301)
Company Profile (289)
Press Release (650727)
Section
Business (204141)
Career Advice (2003)
Deals (35412)
Drug Delivery (89)
Drug Development (80969)
Employer Resources (168)
FDA (16118)
Job Trends (14830)
News (345037)
Policy (32477)
Tag
Academia (2531)
Alliances (49322)
Alzheimer's disease (1288)
Approvals (16081)
Artificial intelligence (160)
Bankruptcy (354)
Best Places to Work (11608)
Biotechnology (206)
Breast cancer (204)
Cancer (1515)
Cardiovascular disease (120)
Career advice (1667)
CAR-T (106)
Cell therapy (309)
Clinical research (64973)
Collaboration (564)
Compensation (304)
COVID-19 (2555)
C-suite (131)
Data (1465)
Diabetes (185)
Diagnostics (6197)
Earnings (85043)
Employer resources (146)
Events (110480)
Executive appointments (471)
FDA (16884)
Funding (509)
Gene therapy (217)
GLP-1 (618)
Government (4338)
Healthcare (18754)
Infectious disease (2652)
Inflammatory bowel disease (115)
Interviews (310)
IPO (16399)
Job creations (3634)
Job search strategy (1420)
Layoffs (424)
Legal (7871)
Lung cancer (222)
Manufacturing (214)
Medical device (13232)
Medtech (13237)
Mergers & acquisitions (19269)
Metabolic disorders (488)
Neuroscience (1647)
NextGen: Class of 2025 (6517)
Non-profit (4472)
Northern California (1860)
Obesity (279)
Opinion (185)
Patents (132)
People (56696)
Phase I (20231)
Phase II (28617)
Phase III (21314)
Pipeline (610)
Postmarket research (2562)
Preclinical (8567)
Radiopharmaceuticals (239)
Rare diseases (284)
Real estate (5906)
Regulatory (21800)
Research institute (2313)
Resumes & cover letters (350)
Southern California (1605)
Startups (3572)
United States (16544)
Vaccines (576)
Weight loss (193)
Date
Last 7 days (655)
Last 30 days (1876)
Last 365 days (34854)
2025 (1562)
2024 (35286)
2023 (40105)
2022 (51230)
2021 (55762)
2020 (54126)
2019 (46568)
2018 (35042)
2017 (32144)
2016 (31522)
2015 (37590)
2014 (31361)
2013 (26382)
2012 (28585)
2011 (29284)
2010 (27353)
Location
Africa (713)
Arizona (203)
Asia (37458)
Australia (6125)
California (4219)
Canada (1545)
China (358)
Colorado (190)
Connecticut (201)
Europe (80175)
Florida (594)
Georgia (146)
Illinois (411)
Indiana (239)
Maryland (681)
Massachusetts (3258)
Michigan (182)
Minnesota (316)
New Jersey (1178)
New York (1197)
North Carolina (781)
Northern California (1860)
Ohio (152)
Pennsylvania (1001)
South America (1093)
Southern California (1605)
Texas (611)
Utah (119)
Washington State (428)
690,317 Results for "sillajen biotherapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
SillaJen, Inc. (KOSDAQ: 215600) has submitted CSR to the US FDA on 06 Feb 2024 for REN026, a phase 1b/2a dose escalation and safety/efficacy evaluation study of Pexa-Vec in combination with cemiplimab in patients with metastatic or unresectable renal cell carcinoma (RCC).
March 27, 2024
·
5 min read
Press Releases
Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq
October 18, 2024
·
4 min read
Business
Mid-Atlantic BioTherapeutics, Inc. and SMITM Capital Markets Ltd enter into a significant financing agreement
SMITM CAPITAL MARKETS LTD, has announced a significant agreement with Mid-Atlantic BioTherapeutics, Inc. (MABT), a clinical-stage ready US biopharmaceutical company.
June 19, 2024
·
4 min read
Press Releases
Chrysalis BioTherapeutics, Inc. Announces Collaboration with NIAID to Evaluate Chrysalin® for the Treatment of Cutaneous Radiation Injury
November 18, 2024
·
2 min read
Press Releases
NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)
October 21, 2024
·
3 min read
Deals
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering
Calidi Biotherapeutics, Inc. today announced the pricing of its “reasonable best efforts” public offering of 15,197,500 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying Series A Common Warrants.
April 16, 2024
·
5 min read
Biotech Beach
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 07, 2024
Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of 9,700 restricted stock units of Atara’s common stock to one newly hired employee.
June 7, 2024
·
2 min read
Biotech Beach
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering
Calidi Biotherapeutics, Inc. announced the closing of its previously announced public offering of 15,197,500 shares of common stock and accompanying Series A Common Warrants, Series B Unit Warrants, with each unit consisting of one share of common stock and a Series B-1 Common Warrant and Series C Unit Warrants.
April 19, 2024
·
4 min read
Biotech Beach
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 05, 2024
Atara Biotherapeutics, Inc. reported the grant of 3,750 restricted stock units of Atara’s common stock to one newly hired employee.
April 5, 2024
·
2 min read
Press Releases
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)
January 16, 2025
·
9 min read
1 of 69,032
Next
